CymaBay plans common stock offering

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
PODCASTS
SEE ALL EPISODES
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
In PersonCorporate Actions & Securities Processing 2023 EMEA User Group Forum
- 06/14/2023
- Druids Glen Hotel & Golf Resort
- 8:00 am - 5:00 pm
WebinarSustainable Datacenters: The Intersection of Innovation and Lifecycle Design
- 06/06/2023
- Live, Online
- 11:00 am -12:00 pm EDT
WebinarHow to Adapt to Digital Disruption in Financial Services: Driving change through digital experiences and flexible data delivery
- 06/08/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: Loan delinquencies up; US money supply falls; coal employment grows

Blog

Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns

Blog

Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

1 Feb, 2017 | 16:50

Author Angelee Tabios
Theme Healthcare & Pharmaceuticals

CymaBay Therapeutics Inc. plans to sell its common stock in an underwritten public offering.

The company intends to use the proceeds of the offering to fund ongoing development of seladelpar and for working capital and general corporate purposes.

JonesTrading Institutional Services LLC is acting as the sole book-running manager, with LifeSci Capital LLC as the lead manager for the offering.